Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors

por Haznedaroğlu, İbrahim C.
Publicado 2013

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)

por Haznedaroglu, Ibrahim C.
Publicado 2014

Drug Therapy in the Progressed CML Patient with multi-TKI Failure

por Haznedaroglu, Ibrahim C.
Publicado 2015

Immunogenomic phases of COVID-19 and appropriate clinical management

por Haznedaroglu, Ibrahim C
Publicado 2020

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

por Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Publicado 2018

Current perspectives for the treatment of chronic myeloid leukemia

por ALADAĞ, Elifcan, HAZNEDAROĞLU, İbrahim Celalettin
Publicado 2019

Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension

por Ciftciler, Rafiye, Haznedaroglu, Ibrahim Celalettin
Publicado 2020

COVID-19, Renin-Angiotensin System, and Hematopoiesis

por Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Publicado 2020

Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat

por HAZNEDAROĞLU, İbrahim Celalettin, ÇELEBİER, Mustafa
Publicado 2020

Ankaferd hemostat: from molecules to medicine

por ÇİFTÇİLER, Rafiye, HAZNEDAROĞLU, İbrahim Celalettin
Publicado 2020

Endothelial Cells, Ankaferd Hemostat, and Estradiol

por Ardıçoğlu, Yasemin, Akar, Nejat, Haznedaroğlu, İbrahim
Publicado 2016

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia

por Malkan, Umit Y., Haznedaroglu, Ibrahim C.
Publicado 2018

Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality

por Bozkurt, Süreyya, Okay, Müfide, Haznedaroğlu, İbrahim
Publicado 2019

Antineoplastic Effects of Ankaferd Hemostat

por Malkan, Umit Yavuz, Haznedaroglu, Ibrahim Celalettin
Publicado 2022

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

por Koluman, Ahmet, Akar, Nejat, Haznedaroğlu, İbrahim C.
Publicado 2017

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

por Okay, Müfide, Çetik, Sıla, Haznedaroğlu, İbrahim C.
Publicado 2019

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

por Okay, Mufide, Ozturk, Yusuf, Haznedaroglu, Ibrahim C.
Publicado 2019

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

por Haznedaroğlu, İbrahim C., Kuzu, Işınsu, İlhan, Osman
Publicado 2020

Perspectives for immune plasma treatment of COVID-19

por SAYINALP, Başak, ÇINAR, Olgu Erkin, HAZNEDAROĞLU, İbrahim Celalettin
Publicado 2021

A New Candidate as a Hemostatic Agent for Difficult Situations During Variceal Bleeding: Ankaferd Blood Stopper

por Ozaslan, Ersan, Purnak, Tugrul, Yildiz, Ayla, Haznedaroglu, Ibrahim C.
Publicado 2011